Alectinib (Alecensaro)

Canada’s Drug Agency (CDA-AMC) recommends that Alecensaro should be reimbursed by public drug plans for adjuvant treatment following tumour resection for patients with stage IB (tumours ≥ 4 cm) to IIIA (according to American Joint Committee on Cancer [AJCC] Cancer Staging Manual, seventh edition) ALK-positive non–small cell lung cancer (NSCLC) if certain conditions are met. Alecensaro should only be covered to treat adult patients (≥ 18 years) who have stage IB (tumour ≥ 4 cm) to stage IIIA (per the AJCC seventh edition) ALK-positive NSCLC, have had complete tumour resection, and are in relatively good health. Alecensaro should only be reimbursed if it is prescribed by clinicians with expertise in managing NSCLC and the cost of Alecensaro is reduced. Alecensaro should be discontinued if a patient’s cancer grows or spreads, if treatment is unacceptably toxic to the patient, or the patient has completed 2 years of therapy with Alecensaro.